Work

Phase 1b study of BXCL701, a novel small molecule inhibitor of dipeptidyl peptidases (DPP), combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.e17581

Authors: Rahul Raj Aggarwal, Dan Costin, Vincent J. O'Neill, Stefani Corsi-Travali, Sreenivas Adurthi, Adedayo Adedoyin, Diane I. Healey, Johann S. De Bono, Paul Monk, Jingsong Zhang, Eric Jay Small

Institutions: UCSF Helen Diller Family Comprehensive Cancer Center, White Plains Hospital, BioXcel Therapeutics, Inc. (United States), Royal Marsden NHS Foundation Trust, Institute of Cancer Research, The Ohio State University, Moffitt Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3030923300

Cites:

Cited by: 7

Related to: 10